What Conditions Can Henoch-Schönlein Purpura Lead To?

Allergic purpura—more accurately termed Henoch-Schönlein purpura (HSP) in modern medical literature—is a systemic small-vessel vasculitis primarily affecting children, though adults can also be affected. It is characterized by immunoglobulin A (IgA)-mediated inflammation of postcapillary venules, leading to leukocytoclastic vasculitis.

The hallmark clinical triad includes palpable purpura (typically symmetric and located on the lower extremities and buttocks), abdominal pain, and arthralgia or arthritis. However, HSP is a multisystem disorder with potential involvement beyond these features. Cutaneous manifestations are universal and often the presenting sign; the purpuric lesions result from IgA immune complex deposition in dermal vessel walls, causing extravasation of red blood cells.

Gastrointestinal involvement occurs in approximately 50–75% of cases and may range from mild colicky abdominal pain and nausea to severe complications such as intussusception, gastrointestinal bleeding, or bowel perforation—particularly in older children and adults.

Renal involvement—termed IgA vasculitis nephritis—develops in 20–60% of patients, typically within days to weeks after onset. It manifests as hematuria (often microscopic), proteinuria, and occasionally nephrotic-range proteinuria or acute kidney injury. While most pediatric cases resolve spontaneously, a subset—especially adults and those with persistent hypertension, significant proteinuria, or crescentic glomerulonephritis on biopsy—may progress to chronic kidney disease or end-stage renal disease.

Joint involvement is common but usually self-limited, presenting as transient, non-erosive arthritis or arthralgia, predominantly affecting the knees and ankles. Rarely, testicular involvement (orchitis) or central nervous system manifestations—including headache, seizures, or encephalopathy—may occur, reflecting vasculitic involvement of other organ systems.

Long-term follow-up is essential, particularly for patients with renal involvement, as late-onset nephropathy can emerge months to years after initial presentation. Management remains supportive in most cases, with corticosteroids considered for severe gastrointestinal or renal disease, though evidence for their impact on long-term renal outcomes remains inconclusive.